Maria Vargas-Soria1, Maria Jose Carranza-Naval1,2, Angel Del Marco3, Monica Garcia-Alloza4. 1. Division of Physiology, School of Medicine, Instituto de Investigacion Biomedica de Cadiz (INIBICA), Universidad de Cadiz, Edificio Andres Segovia, C/Dr. Maranon 3, 3er piso, Cadiz, Spain. 2. Salus Infirmorum-Universidad de Cadiz, Cadiz, Spain. 3. Division of Physiology, School of Medicine, Instituto de Investigacion Biomedica de Cadiz (INIBICA), Universidad de Cadiz, Edificio Andres Segovia, C/Dr. Maranon 3, 3er piso, Cadiz, Spain. angeljose.delmarco@uca.es. 4. Division of Physiology, School of Medicine, Instituto de Investigacion Biomedica de Cadiz (INIBICA), Universidad de Cadiz, Edificio Andres Segovia, C/Dr. Maranon 3, 3er piso, Cadiz, Spain. monica.garcia@uca.es.
Abstract
BACKGROUND: The described relationship between Alzheimer's disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD pathology. MAIN BODY: Although T2D treatment has evident limitations, options are increasing including glucagon-like peptide 1 analogs. Among these, liraglutide (LRGT) is commonly used by T2D patients to improve β cell function and suppress glucagon to restore normoglycaemia. Interestingly, LRGT also counterbalances altered brain metabolism and has anti-inflammatory properties. Previous studies have reported its capacity to reduce AD pathology, including amyloid production and deposition, tau hyperphosphorylation, or neuronal and synaptic loss in animal models of AD, accompanied by cognitive improvement. Given the beneficial effects of LRGT at central level, studies in patients have been carried out, showing modest beneficial effects. At present, the ELAD trial (Evaluating Liraglutide in Alzheimer's Disease NCT01843075) is an ongoing phase IIb study in patients with mild AD. In this minireview, we resume the outcomes of LRGT treatment in preclinical models of AD as well as the available results in patients up to date. CONCLUSION: The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment. While studies in patients are limited, ongoing clinical trials will probably provide more definitive conclusions on the role of LRGT in AD patients.
BACKGROUND: The described relationship between Alzheimer's disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD pathology. MAIN BODY: Although T2D treatment has evident limitations, options are increasing including glucagon-like peptide 1 analogs. Among these, liraglutide (LRGT) is commonly used by T2D patients to improve β cell function and suppress glucagon to restore normoglycaemia. Interestingly, LRGT also counterbalances altered brain metabolism and has anti-inflammatory properties. Previous studies have reported its capacity to reduce AD pathology, including amyloid production and deposition, tau hyperphosphorylation, or neuronal and synaptic loss in animal models of AD, accompanied by cognitive improvement. Given the beneficial effects of LRGT at central level, studies in patients have been carried out, showing modest beneficial effects. At present, the ELAD trial (Evaluating Liraglutide in Alzheimer's Disease NCT01843075) is an ongoing phase IIb study in patients with mild AD. In this minireview, we resume the outcomes of LRGT treatment in preclinical models of AD as well as the available results in patients up to date. CONCLUSION: The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment. While studies in patients are limited, ongoing clinical trials will probably provide more definitive conclusions on the role of LRGT in ADpatients.
Entities:
Keywords:
Alzheimer’s disease; Amyloid; Cognition; Inflammation; Liraglutide; Tau
Authors: Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan Journal: Nat Rev Neurol Date: 2018-01-29 Impact factor: 42.937
Authors: Katharina Timper; Almudena Del Río-Martín; Anna Lena Cremer; Stephan Bremser; Jens Alber; Patrick Giavalisco; Luis Varela; Christian Heilinger; Hendrik Nolte; Aleksandra Trifunovic; Tamas L Horvath; Peter Kloppenburg; Heiko Backes; Jens C Brüning Journal: Cell Metab Date: 2020-05-19 Impact factor: 27.287
Authors: Henry Querfurth; John Marshall; Keykavous Parang; Mengia S Rioult-Pedotti; Rakesh Tiwari; Bumsup Kwon; Steve Reisinger; Han-Kyu Lee Journal: PLoS One Date: 2022-01-21 Impact factor: 3.240